1. Home
  2. PRTC

as 06-20-2025 4:00pm EST

$
-
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Founded: 2015 Country:
United States
United States
Employees: N/A City: N/A
Market Cap: 439.8M IPO Year: N/A
Target Price: $45.00 AVG Volume (30 days): 2.0K
Analyst Decision: Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: 0.21 EPS Growth: N/A
52 Week Low/High: $13.30 - $28.39 Next Earning Date: 04-30-2025
Revenue: $4,828,000 Revenue Growth: 44.98%
Revenue Growth (this year): 35.98% Revenue Growth (next year): 115.38%

PRTC Daily Stock ML Predictions

Share on Social Networks: